title: GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease.
abstract: Non-alcoholic fatty liver disease (NAFLD), one of the most common liver diseases, is caused by the disruption of hepatic lipid homeostasis. It is associated with insulin resistance as seen in type 2 diabetes mellitus. Glucagon-like peptide-1 (GLP-1) is an incretin that increases insulin sensitivity and aids glucose metabolism. In recent in vivo and in vitro studies, GLP-1 presents a novel therapeutic approach against NAFLD by increasing fatty acid oxidation, decreasing lipogenesis, and improving hepatic glucose metabolism. In this report, we provide an overview of the role and mechanism of GLP-1 in relieving NAFLD.
authors.affiliation: Institute of Medical Research, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
authors.forename: Jinmi
authors.initials: J
authors.lastname: Lee
authors.forename: Seok-Woo
authors.initials: SW
authors.lastname: Hong
authors.forename: Eun-Jung
authors.initials: EJ
authors.lastname: Rhee
authors.forename: Won-Young
authors.initials: WY
authors.lastname: Lee